Phase I Trial of Anti-CD74 (hLL1) Antibody Therapy in B Cell Malignancies.

Trial Profile

Phase I Trial of Anti-CD74 (hLL1) Antibody Therapy in B Cell Malignancies.

Completed
Phase of Trial: Phase I

Latest Information Update: 13 Feb 2017

At a glance

  • Drugs Milatuzumab (Primary)
  • Indications Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma
  • Focus Adverse reactions
  • Most Recent Events

    • 18 Nov 2010 Results will presented at the 52nd ASH Annual Meeting, according to an Immunomedics media release.
    • 24 Jun 2009 Planned end date changed from Dec 2008 to Jun 2010 as reported by ClinicalTrials.gov.
    • 17 Aug 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top